Chemed Corporation (CHE) Stock Price & Analysis
Chemed Corporation (CHE) closed at USD 520.15 on Thursday, October 22, 2026, up 1.72% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 520.15; the Oct 22, 2026 session ranged USD 512.52–522.59 on volume of 141,442 shares. Market capitalization is —, with a 52-week range of USD 365.21–557 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CHE.md
Key facts (CHE)
- Last four reported quarters (through Jun 30, 2026): revenue $2.60B, net income $275M (10.6% margin), free cash flow $323M (SEC filings).
- Valuation: P/E 24.7x (avg 27.5x at the last 3 fiscal year-ends), EV/EBITDA 16.8x, net debt $99.8M.
- Insider open-market sales, last ~7 months: 10 Form 4 filings, $6.5M; 10 not under a Rule 10b5-1 plan ($6.5M); 3 by opportunistic insiders (3 outside 10b5-1 plans), 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +20.1% vs S&P 500 +14.9%; 5Y +17.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 6.44, revenue estimate $685M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CHE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.14B | $2.13B | $2.26B | $2.43B | $2.53B | $2.60B |
| Gross profit | $770M | $765M | $799M | $854M | $823M | — |
| Operating income | $343M | $343M | $341M | $366M | $338M | $349M |
| Net income | $269M | $250M | $273M | $302M | $265M | $275M |
| EPS (diluted) | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 | — |
| Free cash flow | $250M | $253M | $273M | $368M | $325M | $323M |
| Gross margin | 36.0% | 35.8% | 35.3% | 35.1% | 32.5% | — |
| Operating margin | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% | 13.5% |
| Net margin | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% | 10.6% |
| Revenue growth | +2.9% | -0.2% | +6.1% | +7.4% | +4.1% | — |
| Cash + short-term investments | $32.9M | $74.1M | $264M | $178M | $74.5M | — |
| Total debt | $185M | $97.5M | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CHE)
P/E 24.7x · P/S 2.6x · EV/EBITDA 16.8x · EV/Sales 2.7x · P/FCF 21.0x · P/B 8.2x · FCF yield 4.76% · Earnings yield 4.05% · Dividend yield (paid, TTM) 0.49% · Buyback yield (TTM) 9.46% · Net debt $99.8M · EV $6.90B
P/E at fiscal year-ends: Dec 2025 23.3x, Dec 2024 26.6x, Dec 2023 32.6x.
Insider sales (SEC Form 4, open-market, last ~7 months) (CHE)
0 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | McNamara Kevin J | president and CEO | 2,000 | $1.0M | 2.9% | No | Routine (sold in May & Aug each year 2023–2025; this trade is outside those months) |
| 2026-09-18 | McNamara Kevin J | president and CEO | 2,000 | $1.0M | 2.8% | No | Routine (sold in May & Aug each year 2023–2025; this trade is outside those months) |
| 2026-08-21 | Lee Spencer S | executive vice president | 1,000 | $541K | 6.7% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-21 | McNamara Kevin J | president and CEO | 2,000 | $1.1M | 2.8% | No | Routine (sold in May & Aug each year 2023–2025) |
| 2026-08-03 | McNamara Kevin J | president and CEO | 2,000 | $1.1M | 2.8% | No | Routine (sold in May & Aug each year 2023–2025) |
| 2026-07-31 | Grace Patrick P | Director | 190 | $101K | 5.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-09 | Lindell Andrea R | Director | 1,347 | $603K | 22.7% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-29 | Walsh George J Iii | Director | 500 | $219K | 12.1% | No | Too little history (no open-market trades in 2023) |
| 2026-05-08 | Grace Patrick P | Director | 60 | $26K | 1.8% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-01 | McNamara Kevin J | president and CEO | 2,000 | $842K | 2.2% | No | Routine (sold in May & Aug each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CHE)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | UBS | Initiated | Buy | $650 |
| 2026-07-31 | Oppenheimer | Target raised | Outperform | $500 → $590 |
| 2026-07-30 | RBC Capital | Target raised | Sector Perform | $436 → $548 |
| 2026-07-09 | B of A Securities | Target raised | Neutral | $450 → $510 |
Total return (dividends reinvested) (CHE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +20.1% | +17.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +20.2% | +3.3% |
| Volatility (annualized) | 29.6% | 24.0% |
| Max drawdown | -23.0% (Feb 2026→Mar 2026) | -42.7% (Mar 2024→Mar 2026) |
CHE revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Segment Vitas | $443.3M | 65.9% | +11.9% |
| Segment Roto Rooter | $229.9M | 34.1% | +3.3% |
| Total revenue | $673.3M | 100% | — |
CHE revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Care Services | $446.4M | 66.3% | +7.6% |
| — Routine Home Care (part of Care Services) | $391.3M | 58.1% | +9.3% |
| — Inpatient Care (part of Care Services) | $35.7M | 5.3% | +8.0% |
| — Continuous Care (part of Care Services) | $19.4M | 2.9% | -18.0% |
| Contractor Revenue | $17.1M | 2.5% | -1.9% |
| Franchise Fees | $1.4M | 0.2% | +2.7% |
| Other Short Term Core Service Jobs | $272,000 | 0.0% | +45.5% |
| Total revenue | $673.3M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CHE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Roto-Rooter | “Roto-Rooter's safety program is designed to help ensure the safety of our employees and customers.” |
| Customer | VITAS Healthcare | “These additional costs, in the case of VITAS, cannot be passed along to our patients because of the structure of hospice reimbursement, and in the case of Roto-Rooter, may not be able to be fully passed along to our customers.” |
Quoted from the company's 10-K filed Feb 27, 2026.
CHE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $6.44 | $6.02 | +6.9% | $685.0M | 5 |
| Next quarter (ends Dec 2026) | $7.37 | $7.07 | +4.3% | $705.3M | 5 |
| Current fiscal year (ends Dec 2026) | $25.49 | $24.34 | +4.7% | $2.72B | 5 |
| Next fiscal year (ends Dec 2027) | $27.52 | $26.88 | +2.4% | $2.89B | 5 |
Key Statistics (as of October 23, 2026 at 10:01 UTC)
| Price | USD 520.15 |
|---|---|
| Change | ▲ 1.72% (up) |
| Previous Close | USD 520.15 |
| Open | USD 520.15 |
| Day Range | USD 512.52 – 522.59 |
| 52-Week Range | USD 365.21 – 557 |
| Volume | 141,442 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CHE)
Nexqual's technical model rates CHE "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.11 (neutral) |
| vs SMA50 | Above (USD 515.73) |
| MACD | 0.69 (positive) |
Earnings (CHE)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 6.44 |
| Revenue Estimate | $685.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 6.06 vs est 5.6 ▲ beat |
| 2026-03-31 | USD 5.65 vs est 5.3 ▲ beat |
| 2025-12-31 | USD 6.42 vs est 7.03 ▼ miss |
| 2025-09-30 | USD 5.27 vs est 5.37 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financials & Fundamentals (CHE)
| Total Revenue | $2.60B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.80% |
| Gross Margin | +33.11% |
| Operating Margin | +13.25% |
| Profit Margin | +10.60% |
| ROE | +27.11% |
| Debt / Equity | 0.35 |
| Current Ratio | 0.91 |
| Total Cash | $40.22M |
| Total Debt | $294.79M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $323.47M (12.5% of revenue) |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financial Health Score (CHE)
Nexqual rates Chemed Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:01 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 13% (last 12 months) |
| Balance Sheet | Mixed — $40M cash and investments vs $140M debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $323M (last 4 quarters to Jun 2026, SEC), 12% margin |
| Efficiency | Strong — ROE 27%, ROA 13.5% |
Ownership (CHE)
| Insider Ownership | +1.94% |
|---|---|
| Institutional Ownership | +106.24% |
| Shares Outstanding | 13.07M |
| Float | 11.85M |
| Short % of Float | +5.38% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Leadership (CHE)
Chemed Corporation is led by Kevin J. McNamara, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:01 UTC.
| CEO, President & Director | Kevin J. McNamara |
|---|---|
| Executive VP, Controller, Principal Accounting Officer & CFO | Michael D. Witzeman |
| Executive Vice President | Spencer S. Lee |
| VP & Director | Thomas C. Hutton |
| Executive VP and President & CEO of VITAS Healthcare | Joel L. Wherley |
Major Backers & Investors (CHE)
Notable institutional backers of Chemed Corporation include AQR Capital Management, LLC, Acadian Asset Management. LLC, JPMorgan, according to Nexqual as of October 23, 2026 at 10:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 7.44% |
| Acadian Asset Management. LLC | 3.47% |
| JPMorgan | 3.09% |
| Boston Partners | 2.15% |
| Epoch Investment Partners, Inc. | 2.05% |
| John Hancock Funds III-Disciplined Value Mid Cap Fund | 1.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.36% |
| Vanguard Group | 10.64% |
| State Street | 3.4% |
| Geode Capital | 3.17% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
From Chemed Corporation's Latest SEC 10-K Filing (filed 2026-02-27)
Partnerships
- Violations of the Anti-Kickback Law carry potentially severe penalties including imprisonment of up to ten years, criminal fines of up to $100,000 per act, civil money penalties of up to $100,000 per act, and additional damages of up to three times the amounts claimed or remuneration offered or paid.
- In connection with the settlement, VITAS and certain of its subsidiaries entered into a corporate integrity agreement ("CIA") on October 30, 2017.
Legal & Regulatory Risks (Item 1A, quoted)
- Our operations are subject to numerous laws and regulations, exposing us to potential claims and compliance costs that could adversely affect our business.
- Environmental and safety compliance costs and liabilities could increase our expenses and adversely affect our financial condition.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| CON | Concentra Group Holdings Parent | USD 39.97 | ▲ 2.25% |
| OPCH | Option Care Health, Inc. | USD 31.29 | ▼ 0% |
| LFST | LifeStance Health Group, Inc. | USD 12.56 | ▲ 1.87% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt